Anthony King~~Sonya Ho~~Ddang (Paul) Kim~~Étienne Renaudeau~~Sarah Chaudhuri~~Luke Cowdell~~Makiko Harunari~~Chenyu Cui~~Meredith Jones~~Paul Jansch~~Ron Ben-Yehuda~~Steven Klar~~Gregory Grogan~~J. Struhs
January 24, 2026
Blackstone to Sell Alinamin Pharmaceutical Co., Ltd.

1 min
AI-made summary
- Simpson Thacher is advising Blackstone on the sale of Alinamin Pharmaceutical Co., Ltd
- to MBK Partners
- Blackstone will retain a minority stake in Alinamin after the transaction closes
- The financial terms of the deal have not been disclosed
- Alinamin is a Japanese consumer healthcare company specializing in supplements and nonprescription drugs
- Simpson Thacher previously represented Blackstone in its 2021 acquisition of Alinamin from Takeda Pharmaceutical.
Simpson Thacher is representing Blackstone in connection with its sale of Alinamin Pharmaceutical Co., Ltd. (“Alinamin”) to MBK Partners. Blackstone will re-invest a minority stake in Alinamin upon closing of the sale. Terms of the transaction were not otherwise disclosed.~~Alinamin is a leading consumer healthcare company in Japan focusing on supplements and nonprescription drugs. The Firm also represented Blackstone on its acquisition of Alinamin in 2021 from Takeda Pharmaceutical.~~The Simpson Thacher team includes Anthony King, Sonya Ho, Paul Kim and Tiffany Shih (M&A); Étienne Renaudeau, Sarah Chaudhuri and Luke Cowdell (Antitrust); Makiko Harunari and Chenyu Cui (Banking & Credit); Meredith Jones and Paul Jansch (Tax); Ron Ben-Yehuda (Intellectual Property); Steven Klar and Richard Zhang (Funds); and Gregory Grogan and Pasco Struhs (ECEB).
Article Author
Anthony King~~Sonya Ho~~Ddang (Paul) Kim~~Étienne Renaudeau~~Sarah Chaudhuri~~Luke Cowdell~~Makiko Harunari~~Chenyu Cui~~Meredith Jones~~Paul Jansch~~Ron Ben-Yehuda~~Steven Klar~~Gregory Grogan~~J. Struhs
The Sponsor
